

COMPANY OVERVIEW

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing *voclosporin*, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and dry eye syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally.

RECENT NEWS

Aurinia Establishes at-the-Market Facility

Nov 30 2018, 5:18 PM EST

STOCK OVERVIEW

Symbol	AUPH
Exchange	Nasdaq
Market Cap	518.89m
Last Price	\$6.08
52-Week Range	\$4.41 - \$6.69

12/13/2018 04:00 PM EST

INVESTOR RELATIONS

Celia Economides
Vice President, Public Affairs
IR@auriniapharma.com

MANAGEMENT TEAM

Richard M. Glickman, L.L.D. (Hon)
CEO & Chairman of the Board

Neil Solomons, M.D.
Chief Medical Officer

Michael Martin
Chief Operating Officer

Dennis Bourgeault
Chief Financial Officer

**Robert Huizinga, Ph.D., R.N.,
CNeph(C)**
Executive Vice President, Corporate
Development

Erik Eglite, D.P.M., J.D., M.B.A.
Senior Vice President, General Counsel &
Chief Corporate Compliance Officer

Rashieda Gluck
Senior Vice President, Global Clinical
Operations

Ron Demers
Vice President, Manufacturing and Supply
Chain

Celia Economides
Vice President, Corporate & Public Affairs

Lawrence (Larry) D. Mandt
Vice President, Quality & Regulatory Affairs

Bradley J. Dickerson
General Manager, Americas & Global
Commercial Lead

Sue Evans, MBA, RAC
Head, Regulatory Affairs

Simrat Randhawa, M.D., M.B.A.
Head of Global Medical Affairs

AURINIA PHARMACEUTICALS INC.

#1203-4464 Markham Street
Victoria, BC V8Z 7X8
Canada

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.